Synopsis
0
EU WC
0
VMF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
63
PharmaCompass offers a list of Ethacridine Lactate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ethacridine Lactate manufacturer or Ethacridine Lactate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ethacridine Lactate manufacturer or Ethacridine Lactate supplier.
PharmaCompass also assists you with knowing the Ethacridine Lactate API Price utilized in the formulation of products. Ethacridine Lactate API Price is not always fixed or binding as the Ethacridine Lactate Price is obtained through a variety of data sources. The Ethacridine Lactate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate, including repackagers and relabelers. The FDA regulates 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate supplier is an individual or a company that provides 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate active pharmaceutical ingredient (API) or 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate finished formulations upon request. The 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers may include 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate API manufacturers, exporters, distributors and traders.
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate active pharmaceutical ingredient (API) in detail. Different forms of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate DMFs exist exist since differing nations have different regulations, such as 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate DMF submitted to regulatory agencies in the US is known as a USDMF. 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate USDMF includes data on 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate Drug Master File in Japan (6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate JDMF) empowers 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate JDMF during the approval evaluation for pharmaceutical products. At the time of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate Drug Master File in Korea (6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate. The MFDS reviews the 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF as part of the drug registration process and uses the information provided in the 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers with KDMF on PharmaCompass.
A 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEP of the European Pharmacopoeia monograph is often referred to as a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate Certificate of Suitability (COS). The purpose of a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate to their clients by showing that a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEP has been issued for it. The manufacturer submits a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEP holder for the record. Additionally, the data presented in the 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate DMF.
A 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers with NDC on PharmaCompass.
6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate GMP manufacturer or 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate GMP API supplier for your needs.
A 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CoA (Certificate of Analysis) is a formal document that attests to 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate's compliance with 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate specifications and serves as a tool for batch-level quality control.
6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CoA mostly includes findings from lab analyses of a specific batch. For each 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate EP), 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate USP).
